Details of the Drug Formulations

General Information of Drug (ID: DM6Q7U4)

Drug Name
Lenalidomide Drug Info
Synonyms
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
Indication
Disease Entry ICD 11 Status REF
Adult T-cell leukemia/lymphoma Approved [1]
Advanced cancer 2A00-2F9Z Approved [1]
Complex regional pain syndrome type 1 Approved [1]
Hepatosplenic T-cell lymphoma Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Leukemia Approved [1]
MALT lymphoma Approved [1]
Multiple myeloma 2A83 Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Pain MG30-MG3Z Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma Approved [1]
Splenic marginal zone lymphoma Approved [1]
Testicular lymphoma Approved [1]
Urinary bladder neoplasm Approved [1]
Waldenstrom macroglobulinemia 2A85.4 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Colon cancer 2B90.Z Investigative [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
216326
ChEBI ID
CHEBI:63791
CAS Number
191732-72-6
TTD ID
D0Q5NX
VARIDT ID
DR00261
ACDINA ID
D00353

Full List of Drug Formulations Containing This Drug

Lenalidomide 10 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F11362 Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Lenalidomide 15 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F11363 Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Lenalidomide 2.5 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F11364 Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Lenalidomide 20 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F11365 Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Lenalidomide 25 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F11366 Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
------------------------------------------------------------------------------------
Lenalidomide 5 mg capsule
Company Formulation ID FDA Description
Celgene Corporation F11367 Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
------------------------------------------------------------------------------------

References

1 Lenalidomide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
3 Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE)